

REFERENCES

1. Adakveo (crizanlizumab-tmca) injection package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; September 2022.
2. Clinicaltrials.gov. Study to Assess Safety and Impact of SeIG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients with Pain Crisis (SUSTAIN). NCT01895361. Available at: <https://clinicaltrials.gov/ct2/show/NCT01895361>
3. Ataga KI, Kutlar A, Kanter J, et al: Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med 2017; 376(5):429-439. Available at: <https://www.nejm.org/doi/full/10.1056/NEJMoa1611770> Accessed December 2020.
4. Bender MA, Douthitt Seibel G. Sickle Cell Disease. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1377/> Accessed December 2020.
5. Nevitt, Sarah J et al. Hydroxyurea (hydroxycarbamide) for sickle cell disease. The Cochrane database of systematic reviews vol. 4,4 CD002202. 20 Apr. 2017, Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6478259/> Accessed December 2020.
6. Rees D.C., Gibson J.S. Biomarkers in sickle cell disease. Br J Haematol 2012; 156(4):433–445. Available at: PubMed Accessed December 2020.
7. Thom H, Jansen J, Shafrin J, et al. Crizanlizumab and comparators for adults with sickle cell disease: a systematic review and network meta-analysis. BMJ Open 2020; 10:e034147. doi: 10.1136/bmjopen-2019-034147. Available at: <https://bmjopen.bmj.com/content/bmjopen/10/9/e034147.full.pdf> Accessed December 2020.
8. Ware RE, de Montalembert M, Tshilolo L, Abboud MR. Sickle cell disease. Available at: Lancet. 2017 Jul 15;390(10091):311-323. Available at: [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(17\)30193-9/fulltext](https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)30193-9/fulltext) Accessed December 2019.
9. National Center on Birth Defects and Developmental Disabilities. Last reviewed: October 21, 2019. Available at: <https://www.cdc.gov/ncbddd/sicklecell/data.html> Accessed December 2020.
10. Complications and Treatments of Sickle Cell Disease. Last reviewed: June 3, 2020. Available at: www.cdc.gov/ncbddd/sicklecell/treatment.html Accessed December 2020.
11. Data & Statistics on Sickle Cell Disease. Last reviewed: October 21, 2019. Available at: www.cdc.gov/ncbddd/sicklecell/data.html Accessed December 2020
12. National Institute of Health, National Heart Lung and Blood Institute, Division of Blood Diseases and Resources. Evidence-Based Management of Sickle Cell Disease: Expert Panel Report, 2014. Available at: Link Accessed December 2020.
13. American Society of Hematology. State of sickle cell disease 2016 report. Available at: Link Accessed December 2020.
14. Managing Acute Pain if You Have Sickle Cell Disease. (2022). Retrieved from <https://www.cdc.gov/ncbddd/sicklecell/betterhealthtoolkit/managing-acute-pain.html>
15. Brandow, A. M., Carroll, S. P., Creary, S., Edwards-Elliott, R., Glassberg, J., Hurley, R. W., ... Lang, E. (2020). American Society of Hematology 2020 Guidelines for Sickle Cell Disease: Management of acute and chronic pain. Blood Advances, 4(12), 2656–2701. doi:10.1182/bloodadvances.2020001851

HIGH RISK ALERT

